Results 1 to 10 of about 4,350 (187)

Capecitabine-induced Subacute Cutaneous Lupus Erythematosus [PDF]

Anais Brasileiros de Dermatologia, 2019
Aroni Rocha, Hiram Larangeira de Almeida Jr, Gustavo Zerwes, Umberto Lopes de Oliveira Filho   +3 more
doaj   +6 more sources

Ethambutol‐induced subacute cutaneous lupus erythematosus [PDF]

Kaohsiung Journal of Medical Sciences, 2022
Yi‐Wei Huang, Wei‐Hsin Wu
doaj   +6 more sources

Subacute cutaneous lupus erythematosus with a psoriasiform presentation: A diagnostic clinical conundrum [PDF]

Clinical Case Reports, 2023
Key Clinical Message For practitioners experiencing worsening psoriasis, subacute cutaneous lupus erythematosus (SCLE) with a psoriasiform presentation should be ruled out.
Shazli Razi, Thu M. Truong, Palveen Sekhon, Samantha Ouellette, Babar K. Rao   +4 more
doaj   +4 more sources

Amlodipine-Induced Subacute Cutaneous Lupus Erythematosus Localized to Non-Sun-Exposed Areas [PDF]

Case Reports in Dermatology, 2022
The cutaneous manifestations of subacute cutaneous lupus erythematosus (SCLE), a subset of cutaneous lupus erythematosus, arise most often in sun-exposed areas.
Takahiro Mizuta, Miyuki Kato
doaj   +4 more sources

Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab – a case report [PDF]

Frontiers in Immunology, 2023
IntroductionThe anti-programmed cell death protein 1 (PD-1) antibody cemiplimab has shown promising results in the treatment of unresectable or metastatic squamous cell carcinoma, however, frequently leads to immune-related adverse events limiting ...
Simon Fietz, Anne Fröhlich, Cornelia Mauch, Cornelia Mauch, Luka de Vos-Hillebrand, Tanja Fetter, Jennifer Landsberg, Friederike Hoffmann, Judith Sirokay   +8 more
doaj   +2 more sources

Case Report: Subacute cutaneous lupus erythematosus induced by the anti-PD-1 antibody camrelizumab combined with chemotherapy [PDF]

Frontiers in Immunology
The use of immune checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAE), of which skin irAE is common, affecting up to 50% of ICI-treated patients.
Hejing Bao, Hejing Bao, Jiani Zhang, Xi Luo, Xi Luo, Xiaojing Song, Juan Li, Juan Li, Nan Mao, Fang Chen, Hehong Bao, Jiazhu Hu, Jiazhu Hu, Xiaolong Cao, Xiaolong Cao, Shudong Ma, Liping Lin, Liping Lin   +17 more
doaj   +2 more sources

A patient with subacute cutaneous lupus erythematosus along Blaschko lines: Implications for the role of keratinocytes in lupus erythematosus

Dermatologica Sinica, 2016
Blaschko lines are manifestations of cutaneous mosaicism, with apparent contrast between normal cells and abnormal cells, which carry postzygotic mutations.
Sebastian Yu, Hsin-Su Yu
doaj   +2 more sources

Drug-induced subacute cutaneous lupus erythematosus secondary to Dupilumab: A case report [PDF]

SAGE Open Medical Case Reports
We present the case of a 63-year-old male with known rheumatoid arthritis, diabetes, hypertension, and peripheral neuropathy who developed drug-induced subacute cutaneous lupus erythematosus secondary to Dupilumab for his chronic hand dermatitis.
Miranda Waugh, Geneviève Gavigan
doaj   +2 more sources

A Case Report of a Rare Subacute Cutaneous Lupus Erythematosus with Chin Prostration [PDF]

Clinical, Cosmetic and Investigational Dermatology
Wanni Li,1,2,* Wen Luo,1,* Yujia Liang,1,2 Ping Wang,1,2 Chunxia Wang,1,2 Jiejie Lu,1,2 Weiwei Wu1,2 1Department of Dermatology, Affiliated Dermatology Hospital of Hainan Medical University, Haikou, People’s Republic of China; 2Department
Li W, Luo W, Liang Y, Wang P, Wang C, Lu J, Wu W   +6 more
doaj   +2 more sources

Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report [PDF]

Frontiers in Immunology
Immune checkpoint inhibitors (ICIs) have become a standard treatment for various cancers, but their use is often associated with immune-related adverse events (irAEs), including cutaneous irAEs (cirAEs).
Chenxi Zhang, Xiaoying Zhang, Jiali Liang, Yifei Liu, Jialong Chen, Qi Wang, Changxing Li, Changxing Li   +7 more
doaj   +2 more sources